Brainever

Homeoprotein Therapies for ALS, Parkinson’s, Retina

Paris, France · Founded 2015 · $36.3M raised

Headquarters
Paris
Founded
2015
Business Model
B2B
Total Funding
$36.3M
Last Round
$36.3M Series BJul 2025
Rounds
1

About

BrainEver is a Paris-based biopharmaceutical company developing a pipeline of novel therapies for patients suffering from age-related neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and retinal conditions. Its approach, based on homeoprotein biology, aims to halt disease progression by stopping neuronal death and durably modifying the physiology and metabolism of surviving neurons. The company secured €33M in Series B funding to advance Europe's first clinical trial of its ALS treatment.

Summary

Brainever is a Biotech company based in Paris, France, founded in 2015. It has raised $36.3M in total across 1 round, most recently a $36.3M Series B round in Jul 2025. Investors include Critical Path, European Innovation Council Fund and iBionext.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJul 2025
$36.3M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Brainever on Indexed.vc
<a href="https://indexed.vc/companies/brainever"><img src="https://indexed.vc/api/badge/company/brainever" alt="Brainever on Indexed.vc" width="260" height="76" /></a>